Varicella Susceptibility in a Canadian Population by Ratnam, Samuel
Varicella susceptibility in a
Canadian population
Sam Ratnam PhD MPH SCM
Can J Infect Dis Vol 11 No 5 September/October 2000 249
ORIGINAL ARTICLE
Newfoundland Public Health Laboratory, Department of Health and Community Services, and Division of Community Health, Faculty of
Medicine, Memorial University of Newfoundland, St John’s, Newfoundland
Correspondence and reprints: Dr S Ratnam, PO Box 8800, Newfoundland Public Health Laboratory, St John’s, Newfoundland A1B 3T2.
Telephone 709-737-6568, fax 709-737-7070, e-mail nphlab@newcomm.net
Received for publication July 12, 1999. Accepted October 26, 1999
S Ratnam. Varicella susceptibility in a Canadian population. Can J Infect Dis 2000;11(5):249-253.
OBJECTIVE: To determine susceptibility to varicella zoster virus (VZV) infection among children, pregnant women and health
care workers in Newfoundland.
DESIGN: Cohort and cross-sectional, province-wide, population-based seroprevalence study.
STUDY POPULATION AND METHODS: A cohort of 586 children aged one year, a cross-sectional group of 1135 school children
aged five to 15 years, 3643 pregnant women aged 15 to 45 years, and 5386 persons in health care settings aged 15 to 55 years.
Susceptibility to varicella was determined by enzyme immunoassay based on serum antibody to VZV.
RESULTS: Among the cohort of 586 children, 565 (96.4%) did not have detectable VZV antibody at one year of age. The propor-
tion with VZV antibody increased thereafter to 12.8% and 33.9%, respectively, at age two and four years, indicating the extent of
exposure to VZV at these ages. Among the 1135 school-age children, the proportion testing positive for VZV antibody increased
from 44% at five years of age to 88.9% at 15 years of age, indicating the cumulative incidence of varicella in this age group.
Among pregnant women, 92.1% tested positive for VZV antibody, and the corresponding figure for the health care group was
93.1%. In both groups, the proportion testing positive for VZV antibody increased with advancing age, from 89.6% for the 15- to
19-year age group to 96.5% for those over the age of 40 years.
CONCLUSIONS: The risk of VZV infection increases steadily from one year of age, reaching a peak during school years. The
study data support the recent Canadian recommendation to vaccinate any person older than 12 months of age who is suscepti-
ble to VZV. Among the adult population, the proportion susceptible will be under 10% for the foreseeable future, and for those at
risk, selective vaccination based on their immune status would be a cost effective approach.
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Sensibilité à la varicelle dans une population canadienne
OBJECTIF : Déterminer la sensibilité au virus varicelle-zona (VZV) chez les enfants, les femmes enceintes et les travailleurs de la
santé de la province de Terre-Neuve.
MODÈLE : Étude de séroprévalence basée dans la population, d’une cohorte et transversale et à l’échelle de la province.
POPULATION À L’ÉTUDE ET MÉTHODES : Une cohorte de 586 enfants d’un an, d’un groupe transversal de 1135 écoliers âgés
de 5 à 15 ans, de 3643 femmes enceintes âgées de 15 à 45 ans, et de 5386 personnes du domaine de la santé âgées de 15 à
55 ans. La sensibilité à la varicelle a été déterminée par une technique immunoenzymatique basée sur la présence d’anticorps
sériques contre le VZV.
RÉSULTATS : Dans la cohorte des 586 enfants, 565 (96,4 %) n’avaient pas d’anticorps contre le VZV décelables à l’âge d’un an.
La proportion d’entre eux porteurs d’anticorps décelables est ensuite passeé respectivement à 12,8 % et à 33,9 %, à l’âge de
deux ans et quatre ans, ce qui révélait l’étendue de l’exposition au VZV à ces âges. Parmi les 1135 écoliers, la proportion ayant
un test positif pour le VZV est passeé de 44 % à l’âge de cinq ans à 88,9 % à l’âge de 15 ans, indiquant l’incidence cumulative de la
varicelle dans ce groupe d’âge. Chez les femmes enceintes, 92,1 % avaient un test positif pour les anticorps anti-VZV, et le chiffre
correspondant pour le groupe des travailleurs de la santé était de 93,1 %. Dans les deux groupes, la proportion ayant un test po-
sitif pour les anticorps contre le VZV a augmenté avec l’âge, passant de 89,6 % dans la tranche d’âge des 15 à 19 ans à 96,5 %
dans celle des plus de 40 ans.
CONCLUSIONS : Le risque d’être infecté par le VZV augmente graduellement à partir de l’âge d’un an pour culminer chez les en-
fants d’âge scolaire. Les données de cette étude étayent la recommandation canadienne récente de vacciner toute personne de
plus de 12 mois sensible au VZV. Dans la population adulte, la proportion sensible sera inférieure à 10 % dans un avenir prévisi-
ble, et pour les individus à risque, une vaccination sélective basée sur leur état immunitaire serait une approche rentable.
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Although varicella is a self-limiting disease in preschooland school-aged children, the risk of complications and
hospitalizations following varicella in healthy children may
be higher than reported a decade ago (1). Also, reports from
the United States and the United Kingdom have indicated an
upward shift in the age distribution of varicella (2-4). This
shift has major public health implications because varicella is
generally more severe in adolescents and adults, and can re-
sult in severe life-threatening complications and death in pre-
viously healthy individuals (5-9). Varicella also has important
consequences for susceptible, pregnant women (3). Varicella
during pregnancy can lead to congenital varicella syndrome in
the fetus, and perinatal exposure can result in severe neonatal
varicella with a fatality rate of as much as 20% (10). Noso-
comial varicella can be both costly to the hospital and disrup-
tive to patient care, and susceptible health care workers play a
major role in transmitting the disease in this setting (11-13).
Regardless of a person’s age, varicella may be lethal in the
presence of biological or iatrogenic immunosuppression. The
continuing spread of HIV and the increasing number of indi-
viduals undergoing solid or nonsolid organ transplantation,
along with the changing epidemiology of varicella, are ex-
pected to contribute to future varicella morbidity and mortal-
ity rates (5). The cost of varicella in Canada has been esti-
mated to be $122.4 million/annum or $353/case (14).
Varivax, a live, attenuated varicella virus vaccine (Merck
Frosst Canada and Company, Canada), was recently approved
for routine use in Canada. The Canadian National Advisory
Committee on Immunization has since recommended varicella
vaccine to any person older than 12 months of age who is sus-
ceptible to varicella (14). Following licensing of Varivax in the
United States in 1995, the United States Advisory Committee
on Immunization Practices made a similar recommendation
(6). Varicella immunity is desirable in adolescents and adults,
and there are indications for assessing varicella immune
status for specific populations from the standpoint of vaccina-
tion and other preventive strategies (6,12-14). In view of the
above, and because there is no current information on the pre-
vailing susceptibility to varicella zoster virus (VZV) in the Ca-
nadian population, a study was carried out to assess the
prevalence of VZV antibody among groups of people represen-
tative of the general population in Newfoundland.
STUDY POPULATION AND METHODS
The provincial Public Health Laboratory (PHL) in St John’s,
Newfoundland had access to serum samples previously col-
lected from preschool and school-aged children across the
province for a related study. These specimens were used to de-
termine varicella susceptibility in children of different age
groups in Newfoundland. Routine seroscreening services for
infectious diseases including varicella are centralized at the
PHL, and these services are used for prenatal screening as well
as for pre-employment and student pre-admission screenings.
The above provided the PHL with access to serum specimens
from different age groups of adults representing the general
population in the province.
Study population: The study population was from across the
province, and was divided into the following four groups: pre-
school children; school-aged children; pregnant women; and
persons in health care settings. The preschool group was a co-
hort of 586 children aged one year, 288 females and 298 males,
representing all five health regions in the province. They were
randomly enrolled over a one-year period during 1992 and
1993 in a study dealing with measles immunization strategy.
In connection with this study, blood samples were obtained
from this cohort at one, two and four years of age, and the
leftover serum specimens were used in the present study.
The school-aged group comprised 1135 children, five to 15
years of age. They were enrolled during 1995 in a cross-
sectional study also dealing with the measles immunization
strategy. The number of children in each age group ranged
from 50 (five years old) to 150 (11 years old), and both sexes
were equally represented. To obtain provincial representation,
these children were enrolled through random selection of
schools across the province. A two-stage cluster sampling was
completed in each of five health regions in the province; three
schools were picked at random in each health region, and up
to four classes within each grade in a school were approached
to enrol volunteers.
The pregnant women group comprised 3643 women, 15 to
45 years of age. The number of women in each of five-year age
group ranged from 268 (age 15 to 19 years) to 1139 (age 25 to
29 years), with the exception of the 40- to 45-year age group,
which contained 57 women; 81% were in the 20- to 34-year
age group. This group comprised slightly over one-half of
those women who had their routine prenatal screening per-
formed in the province during 1997. They were included in
the study based on the availability of their leftover serum
specimens.
The group in health care settings comprised 5386 persons,
15 to 55 years of age. The number of persons in each of five-
year age group ranged from 411 (age 45 to 49 years) to 1284
(age 20 to 24 years), with the exception of the 50- to 55-year
age group, which contained 62 persons. This group repre-
sented those whose blood specimens were received for hepati-
tis B, measles, rubella and/or varicella immune status screen-
ing as part of their routine health check during 1997. The
majority in this group were health care workers representing
various medical institutions across the province, and the rest
were those seeking admission into professional schools in
health care settings.
With the exception of pre-employment and pre-admission
varicella immune status screenings which were performed
nominally on request, this study was conducted as an anony-
mous population-based investigation using unidentified lefto-
ver specimens. The information retained on the study subjects
included the age and sex of the patient. This study was ap-
proved by the Human Investigation Committee, Faculty of
Medicine, Memorial University of Newfoundland, St John’s,
Newfoundland.
Laboratory method: Varicella immunoglobulin (Ig) G ELISA
test (Clark Laboratories Inc, USA) was used to determine VZV
antibody status. This test allows for quantitation of varicella
antibody and expression of the same in international units
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(IU). By this test, a reading of less than 0.14 IU indicated non-
immunity, 0.14 to 0.18 IU was an equivocal result, and greater
than 0.18 IU indicated immunity. In comparison with the im-
munofluorescent technique, this test has shown to have a rela-
tive sensitivity of 99.4% and specificity of 97% (package insert,
Clark Laboratories). The Clark assay was found to be compara-
ble with the Behring Enzygnost anti-VZV/IgG (Dade Behring,
Germany) assay in a prestudy in-house evaluation. This test
was performed according to the instructions provided by the
manufacturer, and specimens with equivocal test results were
considered to be negative for VZV antibody for analysis pur-
poses.
RESULTS
Among the cohort of 586 preschool children, 565 (96.4%)
did not have detectable VZV antibody, and two (0.3%) had
equivocal results at one year of age. The proportion testing
positive for VZV antibody increased from 3.2% at one year of
age to 12.8% and 33.9%, respectively, at two and four years of
age, indicating the extent of natural VZV exposure of the co-
hort during these intervals. The cross-sectional study of 1135
school children indicated a steady increase in the proportion
testing positive for VZV antibody, from 44% at five years to
88.9% at 15 years of age, again indicating the cumulative inci-
dence of varicella with advancing age. The above data on the
age-specific prevalence of antibody to VZV for these two
groups of children are shown in Figure 1. Among the 3643
pregnant women screened, 3354 (92.1%) tested positive for
VZV antibody. Similarly, among the 5386 persons in health
care settings, 5013 (93.1%) tested positive for VZV antibody.
In both groups, the proportion testing positive for the antibody
showed an upward trend with advancing age, ie, 89.6%, age
15 to 19 years; 93.2%, age 25 to 29 years; and 96.5%, older
than age 40 years, etc. Throughout the study, those testing
positive for varicella antibody mostly had titres greater than
4 IU/mL.
DISCUSSION
A few population-based studies have been conducted else-
where to determine varicella susceptibility and age-specific in-
cidence of varicella (15-19). The present study was based on a
total population of 10,750 persons, comprising four groups of
people covering the age range of one to 55 years. This sample
size represented the general Newfoundland provincial popu-
lation of approximately 680,000 people. This was a large
scale seroprevalence survey, and it has provided current data
on varicella susceptibility for a representative Canadian popu-
lation. The data obtained in this study are consistent with
those reported for similar populations elsewhere (15-19). The
presence of VZV-specific antibody in the absence of acute VZV
infection is indicative of immunity to varicella, and therefore,
testing for VZV antibody has been a traditional method for the
assessment of varicella immune status. However, because the
cellular immunity plays an important role in protection
against varicella, the absence of VZV antibodies may not nec-
essarily imply susceptibility. On the other hand, and more im-
portantly, not all persons with VZV antibody are immune to
varicella because reinfection can occur in those with a prior
history of varicella (20-22). The present study was a
population-based survey carried out to determine the prevail-
ing levels of susceptibility from the standpoint of varicella
vaccination strategy, and therefore, the absence of VZV anti-
body was used as a marker of no prior exposure to varicella
and, hence, taken to indicate susceptibility. For the same rea-
son, those testing equivocal for the VZV antibodies by the as-
say used in the study were also considered susceptible.
The study data indicated that, among one-year-old chil-
dren, including those with equivocal results, the proportion
susceptible was 96.8%. Because the study showed that 92.1%
of pregnant women had varicella antibody, it can be assumed
that most children would have been born with maternally ac-
quired varicella antibody, but obviously this antibody wanes
to undetectable levels within a year in the majority of children.
Can J Infect Dis Vol 11 No 5 September/October 2000 251
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Figure 1) Age-specific prevalence of antibody to varicella zoster virus in a population from Newfoundland. Based on a total of 1721 children and
includes a cohort of 586 children who were tested at one, two and four years of age, and a cross-sectional group of 1135 children five to 15 years of
age
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The small proportion testing positive for varicella antibody at
this point may represent those with the residual maternally
acquired antibody and/or those already exposed to VZV. Re-
gardless, these data indicate that the risk of infection to vari-
cella, if any, is minimal before one year of age. This risk
increases considerably after this age, both during the pre-
school and early school years, as shown by a steady increase
in the proportion of children testing positive for VZV antibody
(Figure 1). It is worth noting that part of the above data were
generated in a cohort of one-year-old children who were fol-
lowed up over a three-year period. The study data correlated
with Newfoundland provincial disease surveillance data,
which indicate that, over the past two decades, 70% to 85% of
reported cases of varicella were in the five- to 10-year age
group (23). It is also significant that the data generated in this
study based on VZV antibody status of Newfoundland children
correlate very well with the data reported in two other Canadian
studies involving Manitoba and Quebec children, both of which
were obtained via caregiver questionnaires (14,24,25). With the
availability of an effective varicella vaccine, universal varicella
immunization is now considered important for all children
(6,12,14). In this context, the above data clearly support both
the Canadian and the American recommendations to vacci-
nate routinely all susceptible children at 12 to 18 months of
age (6,14).
Varicella occurring during pregnancy is a growing clinical
and public health concern (6,10). In 1997, a total of approxi-
mately 6500 women underwent routine prenatal screening in
the province, and this was estimated to represent over 90% of
pregnancies that occurred in Newfoundland during that year;
the study population of 3643 well represented this group. The
study indicated that the proportion of women testing suscepti-
ble was under 10%, and this falls within the range reported for
general populations elsewhere (26). In the absence of a vacci-
nation program, it is likely that there will be a greater accumu-
lation of susceptible women of childbearing age if there is an
upward shift in the age distribution of varicella as indicated in
British and American populations (2-4). It is worth noting that
there is a trend of increasing rubella susceptibility among
women of childbearing age in Canada who received a single
dose of measles-mumps-rubella vaccine during the 1970s
(27). In this context, it appears that a changing epidemiology
of varicella could lead to a similar trend in VZV susceptibility.
However, this proportion will remain small in the foreseeable
future. Varicella vaccination is recommended for susceptible
women of childbearing age (6,12). As a positive history of
varicella is highly predictive of varicella immunity (15), it will
be cost effective to screen those with a negative or uncertain
history of varicella, and selectively vaccinate those who are
found susceptible. From this standpoint, it may be desirable
and practical to include varicella immune status testing, if in-
dicated, in the routine work-up of prenatal screening. Such a
selective screening approach will undoubtedly provide the op-
portunity to identify susceptible women and facilitate vacci-
nation after delivery, a strategy similar to that of the current
prenatal rubella screening and vaccination program.
Introduction of varicella into the hospital environment
commonly occurs, and nosocomial varicella is a major eco-
nomic and health concern. Varicella in immunocompromised
patients can result in severe and sometimes fatal illness. Pre-
employment screening of all hospital workers for varicella
susceptibility or selective screening of those with a negative
varicella history has been recommended (13,28). With the
availability of an effective varicella vaccine, it will be prudent
to implement such an approach and selectively immunize
those found susceptible. Even without the availability of a
varicella vaccine, varicella screening of health care workers
who have direct patient contact is a routine practice in many
centres, and has been so in Newfoundland for many years. In
the present study, 6.9% tested susceptible, and this is similar
to the figures reported for health care workers in the United
States (29). The proportion susceptible among those in health
care settings in Canada is likely to be well below 10%, and se-
lective screening and vaccination will be a cost effective ap-
proach in this setting (29).
Varicella is of major public health significance, and cost ef-
fectiveness studies have indicated considerable economic and
health benefits with routine varicella vaccination of children
(30-32). Chickenpox is now the leading cause of vaccine-
preventable deaths among immunocompromised children,
and varicella in adults and varicella complications may be
more frequent than previously estimated (1,7-9). Although
less than 5% of varicella cases are reported among adults over
20 years of age, 55% of varicella-related deaths occur in this
age group (7). In addition, herpes zoster is also a public health
and social concern, especially with increasing life spans
(5,33). These facts underscore the public health and economic
consequences of varicella and the need to implement an effec-
tive nationwide varicella immunization program.
REFERENCES
1. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of
varicella and its complications. J Infect Dis 1995;172:706-12.
2. Gray GC, Palinkas LA, Kelley PW. Increasing incidence of
varicella hospitalizations in United States army and navy
personnel: Are today’s teenagers more susceptible? Should
recruits be vaccinated? Pediatrics 1990;86:867-73.
3. Fairley CK, Miller E. Varicella-zoster virus epidemiology –
A changing scene? J Infect Dis 1996;174(Suppl 3):S314-9.
4. Miller E, Vurdien J, Farrington P. Shift in age in chicken pox.
Lancet 1993;341:308-9.
5. Weller TH. Varicella: Historical perspective and clinical overview.
J Infect Dis 1996;174(Suppl 3):S306-9.
6. Prevention of varicella: Recommendations of the Advisory
Committee on Immunization Practices (ACIP). Centers for Disease
Control and Prevention. MMWR Morb Mortal Wkly Rep
1996;45(RR-11):1-36.
7. Varicella-related deaths among adults – United States, 1997.
MMWR Morb Mortal Wkly Rep 1997;46:409-12.
8. Varicella-related deaths among children – United States, 1997.
MMWR Morb Mortal Wkly Rep 1998;47:365-8.
9. Varicella-related deaths – Florida, 1998. MMWR Morb Mortal
Wkly Rep 1999;48:379-81.
10. Grant A. Varicella infection and toxoplasmosis in pregnancy.
J Perinat Neonatal Nurs 1996;10:17-29.
11. Hyams PJ, Stuewe MCS, Heitzer V. Herpes zoster causing
varicella (chickenpox) in hospital employees: Cost of a casual
attitude. Am J Infect Control 1984;12:2-5.
12. Holmes SJ. Review of recommendations of the Advisory
Committee on Immunization Practices, Centers for Disease
Control and Prevention, on varicella vaccine. J Infect Dis
1996;174(Suppl 3):S342-4.
252 Can J Infect Dis Vol 11 No 5 September/October 2000
Ratnam
4
G:...ratnam.vp
Mon Oct 16 16:11:06 2000
Color profile: Disabled
Composite  Default screen
0
5
25
75
95
100
0
5
25
75
95
100
0
5
25
75
95
100
0
5
25
75
95
100
13. Casto DT. Varicella vaccination of health care workers.
Am J Health Syst Pharm 1996;53:2628-35.
14. Health Canada. Statement on recommended use of varicella virus
vaccine. Can Commun Dis Rep 1999;25:1-16.
15. Lieu TA, Black SB, Takahashi H, et al. Varicella serology among
school age children with a negative or uncertain history of
chickenpox. Pediatr Infect Dis J 1998;17:120-5.
16. Kilgore PE, Kruszon-Moran D, van Loon FPL, et al.
Seroprevalence of antibody to varicella in a population-based
survey. 37th Interscience Conference on Antimicrobial Agents
and Chemotherapy. Toronto, September 28 to October 1, 1997.
(Abst)
17. Gil A, Gonzalez A, Dal-Re R, Ortega P, Dominguez V. Prevalence
of antibodies against varicella zoster, herpes simplex (types 1
and 2), hepatitis B and hepatitis A viruses among Spanish
adolescents. J Infect 1998;36:53-6.
18. Struewing JP, Hyams KC, Tueller JE, et al. The risk of measles,
mumps and varicella among young adults: A serosurvey of
US Navy and Marine Corps recruits. Am J Public Health
1993;83:1717-20.
19. Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. Age-
specific incidence of chickenpox. Public Health Rep
1994;109:750-5.
20. Iltis JP, Castellano GA, Gerber P, Le C, Vujcic LK, Quinnan GV Jr.
Comparison of the Raji cell line fluorescent antibody to
membrane antigen test and the enzyme-linked immunosorbent
assay for determination of immunity to varicella-zoster virus.
J Clin Microbiol 1982;16:878-84.
21. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of
reinfection with varicella-zoster virus. J Infect Dis
1983;148:200-5.
22. Gershon AA, Steinbert SP. Persistence of immunity to varicella
in children with leukemia immunized with live attenuated
varicella vaccine. N Engl J Med
1989;320:892-7.
23. Communicable Disease Report, Newfoundland Department of
Health and Social Services.
24. Law BJ, Brownell MD, Walld R, et al. Chickenpox in Manitoba:
A population-based assessment using the Manitoba Health
Services Commission Database. 3rd National Immunization
Conference, Calgary, December 6-9, 1998.
25. Boulianne N, Duval B, De Serres G, et al. History of varicella
in children aged 8 to 10 years old and the perception of their
patients of the usefulness of the varicella vaccine.
3rd National Immunization Conference. Calgary, December 6-9,
1998.
26. Wharton M. The epidemiology of varicella-zoster virus
infections. Infect Dis Clin North Am 1996;10:571-81.
27. Ratnam S, West R, Gadag V, Williams B, Oates E. Rubella
antibody levels in school-aged children in Newfoundland:
Implications for a two-dose rubella vaccination strategy.
Can J Infect Dis 1997;8:85-8.
28. Weitekamp MR, Schan P, Aber RC. An algorithm for the control
of nosocomial varicella-zoster virus infection. Am J Infect Control
1985;13:193-8.
29. Tennenberg AM, Brassard JE, Van Lieu J, Drusin LM. Varicella
vaccination for health care workers at a university hospital:
An analysis of costs and benefits. Infect Control Hosp Epidemiol
1997;18:405-11.
30. Bentsi-Enchill A. Varicella-zoster virus disease and
epidemiology: Seeking better control strategies – Part I.
Can Commun Dis Rep 1998;24:193-8.
31. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine
varicella vaccination program for US children. JAMA
1994;271:375-81.
32. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination
against chickenpox: An analysis of benefits and costs. J Pediatr
1994:124:869-74.
33. Arvin AM. Varicella-zoster virus: overview and clinical
manifestations. Semin Dermatol 1996;15(Suppl 1):4-7.
Can J Infect Dis Vol 11 No 5 September/October 2000 253
Varicella susceptibility in a Canadian population
5
G:...ratnam.vp
Mon Oct 16 16:11:06 2000
Color profile: Disabled
Composite  Default screen
0
5
25
75
95
100
0
5
25
75
95
100
0
5
25
75
95
100
0
5
25
75
95
100
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
